[{"data":1,"prerenderedAt":168},["ShallowReactive",2],{"drug-imiquimod":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":33,"contraindications":71,"warnings":72,"renal":80,"monitoring":81,"interactions":82,"review":83,"examples":86,"atc":87,"iran":89,"links":109,"populations":128,"usApproval":163},"imiquimod",1,{"fa":7,"en":8},"ایمیکیمود کرم","Imiquimod cream","dermatology",{"fa":11,"en":12},"تعدیل‌کننده پاسخ ایمنی","Immune response modifier",[14],{"name":15,"market":16},"Zyclara","US",[18,19,20],"aldara","zyclara","ایمیکیمود",[22],{"id":23,"form":23,"route":24,"label":25,"concentration":26,"markets":28,"refs":29},"cream","topical","Imiquimod 3.75% cream, pump (0.235 g per actuation)",{"amount":5,"unit":27,"perUnit":27},"application",[16],[30],{"source":31,"section":32},"fda-imiquimod","3",[34,55],{"id":35,"disease":36,"label":37,"population":40,"type":44,"unit":45,"dose":46,"refs":50},"warts","genital-warts",{"fa":38,"en":39},"زگیل تناسلی و اطراف مقعد — ۱۲ سال به بالا: شب‌ها تا ۸ هفته","External genital\u002Fperianal warts — ≥12 y: nightly up to 8 weeks",{"minAge":41},{"value":42,"unit":43},12,"year","notCalculated","mg",{"reason":47},{"fa":48,"en":49},"لایه نازک یک بار شب‌ها تا پاک شدن کامل یا حداکثر ۸ هفته؛ هر بار حداکثر ۰٫۲۵ گرم. فقط پوست خارجی (نه داخل واژن یا مقعد).","Thin layer once nightly until clearance or up to 8 weeks; up to 0.25 g per application. External skin only (not intravaginal or intra-anal).",[51,53],{"source":31,"section":52},"2.3",{"source":31,"section":54},"1",{"id":56,"disease":57,"label":58,"population":61,"type":44,"unit":45,"dose":64,"refs":68},"ak","actinic-keratosis",{"fa":59,"en":60},"کراتوز اکتینیک صورت یا سر طاس — دو دوره ۲ هفته‌ای شب‌ها","Actinic keratosis of face or balding scalp — two 2-week nightly cycles",{"minAge":62},{"value":63,"unit":43},18,{"reason":65},{"fa":66,"en":67},"لایه نازک شب‌ها روی کل صورت یا سر طاس، دو دوره ۲ هفته‌ای با ۲ هفته استراحت بین آن‌ها؛ هر بار حداکثر ۰٫۵ گرم.","Thin layer nightly to the entire face or balding scalp, two 2-week cycles separated by 2 weeks off; up to 0.5 g per application.",[69],{"source":31,"section":70},"2.2",[],[73],{"text":74,"refs":77},{"fa":75,"en":76},"واکنش التهابی شدید موضعی (ترشح، زخم)؛ تورم شدید فرج ممکن است احتباس ادرار بدهد؛ علائم شبه‌آنفلوانزا؛ از نور آفتاب و UV پرهیز.","Intense local inflammation (weeping, erosion); severe vulvar swelling may cause urinary retention; flu-like symptoms; avoid sunlight and UV.",[78],{"source":31,"section":79},"5",[],[],[],{"status":84,"reviewer":85,"date":85},"unverified",null,[],[88],"D06BB10",{"status":90,"forms":91,"refs":104},"registered",[92,96,100],{"code":93,"en":94,"fa":95},"06583","IMIQUIMOD 5% TOP CREAM","کرم ایمی‌کیمود ۵ درصد",{"code":97,"en":98,"fa":99},"06034","IMIQUIMOD SACHET","ساشه ایمی‌کیمود",{"code":101,"en":102,"fa":103},"53111","IMIQUIMOD CREAM TOPICAL 5 % 7.5 g","کرم ایمی‌کیمود ۵ درصد ۷٫۵ گرم",[105],{"source":106,"section":107,"url":108},"darooyab-generic","G-1180\u002FImiquimod-Topical","https:\u002F\u002Fwww.darooyab.ir\u002FG-1180\u002FImiquimod-Topical",[110,114,118,122,125],{"kind":111,"url":112,"label":113},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=205971","ANDA205971",{"kind":115,"url":116,"label":117},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=5c19b687-fd29-b22e-e063-6294a90ad67b","FDA Imiquimod 3.75%",{"kind":119,"url":120,"label":121},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa698010.html","Imiquimod Topical",{"kind":123,"url":124,"label":88},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=D06BB10",{"kind":126,"url":108,"label":127},"darooyab","Imiquimod-Topical",{"pregnancy":129,"lactation":138,"pediatric":146,"geriatric":154},{"level":130,"text":131,"quote":134,"refs":135},"caution",{"fa":132,"en":133},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Available data from case reports and case series have not established a drugassociated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes when imiquimod is used during pregnancy.",[136],{"source":31,"section":137},"8.1",{"level":130,"text":139,"quote":142,"refs":143},{"fa":140,"en":141},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of topically administered imiquimod in human milk, the effects on the breastfed infant, or the effects on milk production.",[144],{"source":31,"section":145},"8.2",{"level":130,"text":147,"quote":150,"refs":151},{"fa":148,"en":149},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","External Genital Warts The safety and effectiveness of imiquimod cream for the treatment of EGW in pediatric patients 12 years of age and older have been established.",[152],{"source":31,"section":153},"8.4",{"level":155,"text":156,"quote":159,"refs":160},"ok",{"fa":157,"en":158},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness of imiquimod cream have been observed between subjects 65 years of age and older and younger adult subjects.",[161],{"source":31,"section":162},"8.5",{"kind":164,"refs":165,"id":113},"ANDA",[166],{"source":31,"section":167},"SPL approval \u002F marketing category",1792111457006]